预约演示

更新于：2025-06-26

Finasteride

非那雄胺

更新于：2025-06-26

概要

基本信息

简介Finasteride，商业名称为PROSCAR®，是一种5α-还原酶抑制剂药物，主要用于治疗男性前列腺增生症（BPH），改善症状、降低急性尿潴留的风险以及降低需要手术（包括经尿道前列腺电切术和摘除前列腺）的风险。这种药物于1992年在美国获得首次批准，由默克公司生产。PROSCAR (finasteride)是一种合成的4-氮杂甾体化合物，是一种特异性的类固醇II型5α-还原酶抑制剂，可抑制细胞内的酶将雄激素睾酮转化为5α-二氢睾酮（DHT）。

药物类型

小分子化药

别名

(5alpha,17beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide、Finasteride (JAN/USP/INN)、非那雄胺（奎安）

+ [47]

靶点

5α-reductase

作用方式

抑制剂

作用机制

5α-reductase抑制剂(类固醇5α还原酶抑制剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

+ [3]

非在研机构

南京圣和药业股份有限公司

Merck Sharp & Dohme Corp.Merck Frosst Canada Ltd.

+ [3]

权益机构

Daewoong Pharmaceutical Co., Ltd.

Almirall SA

Inventage Lab, Inc.

+ [2]

最高研发阶段批准上市

首次获批日期

美国 (1992-06-19),

前列腺增生症

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C23H36N2O2

InChIKeyDBEPLOCGEIEOCV-WSBQPABSSA-N

CAS号98319-26-7

关联

143

项与非那雄胺相关的临床试验

NCT06944145

/ Not yet recruiting临床2期IIT

New Treatment Strategies and Epigenetic Biomarker for Management of BPH

SRD5A2 is a critical enzyme for prostatic development and growth, and the SRD5A2 inhibitor, finasteride, is used to treat benign prostatic hyperplasia (BPH). SRD5A2 is absent in 30% of normal adult men, which explains the resistance of a subset of patients to this commonly prescribed drug. This project proposes new combination therapies (5-ARI+raloxifene) and evaluates novel non-invasive biomarkers, based on alternative pathways that lead to prostatic enlargement.

开始日期2025-10-01

申办/合作机构

Beth Israel Deaconess Medical Center, Inc.

NCT06826001

/ Not yet recruiting临床2期IIT

COMPARISON OF EFFICACY OF TOPICAL FINESTERIDE VERSUS TOPICAL MINOXIDAL IN TREATMENT OF ANDROGENETIC ALOPECIA

Androgenetic alopecia (AGA)is the most common form of alopecia. It predominantly affects males, but there has been a significant surge in female preponderance too, over the last decade Minoxidil belong to the anti-hypertensive class but it also affects the potassium channels present in vascular smooth muscles and hair follicles. This potassium channel activity may stimulate the microcirculation around the hair follicles and induces arteriolar vasodilation, thereby encouraging conditions conducive to hair growth Topical administration of finasteride offers the potential to reduce systemic effects related to its mechanism of action by preferentially inhibiting 5-a reductase in the scalp, as has been suggested in recent years so in this study we are going to compare efficacy of topical minoxidil versus topical finasteride in treatment of androgenetic alopecia

开始日期2025-02-01

申办/合作机构

Sheikh Zayed Medical College

TCTR20240926001

/ Active, not recruiting临床3期IIT

Efficacy and safety of different doses of topical finasteride in the treatment of male androgenetic alopecia

开始日期2024-12-16

申办/合作机构-

100 项与非那雄胺相关的临床结果

登录后查看更多信息

100 项与非那雄胺相关的转化医学

登录后查看更多信息

100 项与非那雄胺相关的专利（医药）

登录后查看更多信息

4,288

项与非那雄胺相关的文献（医药）

2025-09-01·PHYTOMEDICINE

Shen-Ying-Yang-Zhen formula promotes angiogenesis around hair follicles, alleviates oxidative stress, and inhibits hair follicle apoptosis through the VEGF/Akt/Caspase-9 signaling axis

Article

作者: Su, Lin ; Zhu, Xiaowen ; Zhang, Huixing ; Ding, Han ; Chen, Junnan ; Zhu, Yangzhuangzhuang ; Xu, Zihang ; Liu, Mingxi ; Qiang, Yan ; Wang, Xiaoyu ; Wang, Wuqing ; Zou, Chunpu ; Hang, Shiyu ; Wang, Qiuyue ; Ouyang, Qianxi

BACKGROUND:

Androgenic alopecia (AGA) represents the most predominant form of hair loss in clinical practice, yet currently approved pharmacological options (e.g., finasteride and minoxidil) face limitations in safety and long-term efficacy. Shen-Ying-Yang-Zhen formula (SYF) is a classical prescription in traditional Chinese medicine to AGA; nevertheless, its specific mechanisms of action in addressing AGA remain to be further explored and elucidated. In our study, we for the first time propose that SYF uniquely reshapes the perifollicular microenvironment through dual regulation of oxidative stress and angiogenesis, thus providing a potential medication for AGA.

METHODS:

In this study, the chemical constituents of SYF were identified using UPLC-MS. An AGA mouse model was established by induction with testosterone propionate (TP), and a human dermal papilla cell (HDPC) model was induced by dihydrotestosterone (DHT). The mechanism underlying SYF treatment for AGA was examined by merging network pharmacology with RNA sequencing, and the findings were corroborated through flow cytometry, multiple immunofluorescences, Western blotting, RT-qPCR, and ELISA techniques.

RESULTS:

In the AGA mouse model, histological analysis revealed that oral administration of SYF significantly increased skin thickness and hair follicle density (2.8-fold vs. TP group, p < 0.001). Immunofluorescence staining further confirmed that SYF treatment promoted a 2.9-fold increase in p-S6-positive hair follicles-indicative of anagen-phase induction (p < 0.001). Network pharmacology and RNA-seq analyses showed that SYF treatment was associated with cellular oxidative stress and the angiogenic microenvironment around AGA hair follicles, which may be related to targets such as VEGF and Akt Additionally, expression of Ki67, SRY-box transcription factor 9, phospho-S6 ribosomal protein (p-S6), and Nrf2 was enhanced in the skin of the SYF-treated mice, whereas reactive oxygen species expression was decreased. RT-qPCR analysis revealed downregulation of follicle degradation-related factors DKK1, IL-6, and TGFβ1, along with decreased Caspase-9 expression and upregulated key targets VEGF and Akt in the VEGF/Akt/Caspase-9 signaling axis. In the DHT-HDPC model, SYF promoted the proliferation of HDPCs and elevated the Bcl-2/Bax ratio, which in turn suppressed apoptosis of HDPCs in vitro.

CONCLUSION:

SYF shows promise as a therapeutic agent for prevention of hair loss by improving oxidative stress and angiogenesis in the area surrounding hair follicles in AGA. It reduces apoptosis in DHT-treated HDPCs by regulating the VEGF/Akt/Caspase-9 signaling axis. This multi-target, systems-level approach highlights SYF's potential as a novel therapeutic agent for AGA.

2025-09-01·NEUROPHARMACOLOGY

Early postnatal inhibition of neurosteroid synthesis changes the later-life adverse outcome of neonatal asphyxia in rats

Article

作者: Welzel, Björn ; Löscher, Wolfgang ; Schmidt, Ricardo

Birth asphyxia (BA) is a common cause of hypoxic-ischemic encephalopathy (HIE), neonatal seizures, and detrimental neurodevelopment. Brain levels of neurosteroids such as allopregnanolone rise in response to acute hypoxic stress, which is thought to represent an endogenous protective mechanism that reduces excitotoxicity in the developing brain. In the present study, we investigated how inhibition of neurosteroid synthesis by the steroid 5α-reductase inhibitor finasteride affects the adverse outcomes of BA/HIE. Intermittent asphyxia was induced in neonatal rats at postnatal day 11. Finasteride (50 mg/kg) was administered immediately before asphyxia. Behavioral and cognitive tests were performed over the subsequent 14 months, which corresponds to ∼50 % of the lifespan of the outbred rat strain used. In contrast to our expectation, finasteride decreased the severity and duration of the neonatal seizures and did not increase mortality. Subsequent behavioral experiments showed no adverse development of motor function, but finasteride-treated rats exhibited increased anxiety-like behavior in the open field, elevated plus-maze, and light-dark box tests. The increased anxiety-like behavior was correlated with enhanced mossy fiber sprouting in the hippocampal CA3a region. While vehicle-treated post-asphyxial rats showed a serious decline in cognitive functions, this was not observed in the finasteride-treated group. One possible explanation of the latter finding is that a significant loss of CA3c neurons in the dorsal hippocampus was only determined in vehicle-treated but not finasteride-treated post-asphyxial rats. Overall, the present study indicates that the role of neurosteroids in BA and its adverse outcome is much more complex than previously thought.

2025-09-01·FOOD CHEMISTRY

The aroma evolution in lotus (Nelumbo nucifera Gaertn.) seed juice: A comprehensive analysis of processing and low-temperature storage effects

Article

作者: Jiang, Xiangfu ; Lu, Xu ; Zhou, Taoyi ; Mao, Sirui ; Lei, Qiuming ; Zheng, Baodong ; Huang, Zhanhong ; Zhou, Fuzhen ; Ma, Shuang

Lotus seed juice has significant potential in the plant-based beverage market owing to its distinctive flavor. However, its sensory quality is significantly influenced by processing and storage conditions. This study examined the effects and underlying mechanisms of fresh squeezing, sterilization, and refrigeration at 4 °C (for 1-6 months) on the aroma profile of lotus seed juice using an electronic nose, gas chromatography-ion mobility spectrometry (GC-IMS), and non-targeted metabolomics. Sterilization processes resulted in vanilla, mint, and ammonia-like flavors due to the accumulation of hexanal, pentanal, and pyrrolidine. One month of refrigeration enhanced fruity and minty flavors, attributed to increased acetone and 6-ethyl acetate-D from fatty acid oxidation and esterification, respectively. However, prolonged refrigeration (six months) introduced undesirable alcoholic and pungent off-flavors caused by slow oxidative degradation (such as 2-propanol and 1-hydroxy-2-propanone). These findings provide valuable insights for improving the preservation methods and quality control strategies for plant-based beverages.

248

项与非那雄胺相关的新闻（医药）

2025-06-23

·药事纵横

瀚合瑞：提供从立项到获批的全流程药学CRO服务 | 7thCMC-China优质推荐

上海瀚合瑞医药科技有限公司：提供制剂项目从立项到获批的全流程药学CRO服务，具备经验丰富的的固体制剂、液体制剂和半固体制剂研发团队，以及完备的工艺和分析研发设备。截至目前，团队已完成近200个仿制药和多个创新药制剂研发服务，多个仿制药项目取得国内首仿或前三仿。上海瀚合瑞医药科技有限公司隶属于天津臻诺医药集团，集团下设上海、天津2大CMC研发中心，2大临床研究中心及临床数据统计中心，以及1家原料生产基地，拥有20多家战略合作原料药和制剂生产基地，员工人数超600人，可为客户提供原料药和制剂产品从项目立项、药学研究、临床研究、委托加工、注册申报到MAH产品运营全生命周期一站式服务。集团技术服务平台01 制剂技术平台● 固体制剂、注射剂、外用制剂全流程开发● 难溶性药物给药技术● 固体分散体技术● 高难度复方制剂开发平台● MAH合作/品种转让02 原料技术平台● 仿制及创新原料药CMC研究● 产品定制研发和生产服务（CDMO）● 含氟中间体和原料药平台● 不对称合成、生物酶催化、连续化等技术应用03 临床技术平台 ● 临床药代动力学● 生物等效性● 临床实验方案设计及研究运营、覆盖Ⅰ-Ⅳ期及真实世界● 分析检测服务重点项目推荐奥匹卡朋胶囊01规格：25mg、50mg适应症：左旋多巴/卡比多巴的辅助治疗，适用于帕金森病(PD)的“off”期发作研发进展：原料药&制剂联合开发，中试阶段多替诺雷片02规格：0.5mg、1mg、2mg适应症：痛风，高尿酸血症研发进展：原料药&制剂联合开发，验证批阶段布地奈德肠溶胶囊03规格：4mg适应症：具有进展风险的原发性IgA肾病成人患者研发进展：小试阶段富马酸依美斯汀缓释胶囊04规格：1mg、2mg适应症：过敏性鼻炎和荨麻疹研发进展：小试阶段盐酸米安色林片05规格：10mg，30mg适应症：治疗的各型抑郁症患者，能解除其抑郁症状研发进展：小试阶段西吡氯铵含片06规格：2mg适应症：用于急性、亚急性咽炎，牙龈炎研发进展：小试阶段地喹氯铵含片07规格：0.25mg适应症：用于急、慢性咽喉炎，口腔黏膜溃疡、齿龈炎研发进展：小试阶段苯磺酸美洛加巴林片/口崩片08规格：2.5mg、5mg、10mg、15mg适应症：糖尿病性周围神经病理性疼痛研发进展：小试阶段乌帕替尼缓释片&口服溶液09规格：片剂：15mg口服溶液：1mg/ml适应症：（片剂）特应性皮炎、类风湿关节炎、银屑病关节炎、溃疡性结肠炎等（口服溶液）2岁及以上患者银屑病关节炎、幼年特发性关节炎研发进展：验证批阶段巴瑞替尼片10规格：2mg、4mg适应症：类风湿关节炎、斑秃、特应性皮炎等研发进展：验证批阶段非奈利酮片11规格：10mg、20mg适应症：二型糖尿病相关的慢性肾病研发进展：原料药&制剂联合开发，审评中盐酸氮卓斯汀鼻喷雾剂12规格：10ml:10mg适应症：过敏性鼻炎研发进展：小试阶段非那雄胺喷雾剂13规格：2.275mg/ml适应症：用于 18 至 41 岁患有轻度至中度脱发（雄激素性脱发）的成年男性的局部治疗，以促进头发生长研发进展：小试阶段玛巴洛沙韦片/干混悬14规格：片剂：20mg、40mg干混悬剂：2mg/ml适应症：甲型和乙型流感研发进展：原料药&制剂联合开发，小试阶段醋酸地非法林注射液15规格：50μg/ml适应症：接受血液透析的患者，治疗慢性肾脏病相关的中度至重度瘙痒（CKD-aP）研发进展：中试阶段注射用西维来司他钠16规格：100mg适应症：用于改善全身性炎症反应综合征的急性肺损伤/急性呼吸窘迫综合征研发进展：小试阶段注射用氨曲南阿维巴坦钠17规格：1.5 g/0.5 g适应症：用于治疗复杂盆腔感染（cIAI）、复杂尿路感染（cUTI）、医院获得性肺炎（HAP）/呼吸机相关肺炎（VAP）等研发进展：小试阶段注射用盐酸依拉环素18规格：50mg适应症：适用于治疗成人复杂性腹腔感染（cIAI）研发进展：小试阶段依达拉奉右莰醇注射用浓溶液19规格：5ml:依达拉奉10mg与右莰醇2.5mg适应症：用于改善急性缺血性脑卒中所致的神经症状、日常生活活动能力和功能障碍研发进展：验证批阶段苹果酸奈诺沙星氯化钠注射液20规格：250mll:苹果酸奈诺沙星0.5g与氯化钠 2.25g适应症：成人社区获得性肺炎研发进展：待申报注射用磷酸左奥硝唑酯二钠21规格：0.125g、0.5g、1g适应症：肠道和肝脏严重的阿米巴病、敏感厌氧菌感染引起的手术后感染等研发进展：中试阶段甲苯磺酸奥马环素片&注射用甲苯磺酸奥马环素22规格：片剂150mg、注射剂100mg适应症：社区获得性细菌性肺炎感染、急性细菌性皮肤和皮肤结构感染研发进展：待申报注射用亚胺西瑞23规格：1.25g（亚胺培南500mg+西司他丁500mg+瑞来巴坦250mg）适应症：成人医院内获得性细菌性肺炎和呼吸机相关性细菌性肺炎、复杂性尿路感染、复杂性腹腔内感染研发进展：小试阶段呋喹替尼胶囊24规格：1mg、5mg适应症：结直肠癌研发进展：原料药&制剂联合开发，小试阶段阿帕他胺片25规格：60mg适应症：非转移性去势抵抗性前列腺癌及转移性去势敏感性的前列腺癌研发进展：原料药&制剂联合开发，审评中注射用卡非佐米26规格：60mg适应症：难治性多发性骨髓瘤研发进展：原料药&制剂联合申报，审评中阿贝西利片27规格：50mg、100mg、150mg适应症：早期乳腺癌；局部晚期或转移性乳腺癌研发进展：原料药&制剂联合开发，中试阶段妥卡替尼片28规格：50mg、150mg适应症：乳腺癌研发进展：原料药&制剂联合开发，中试阶段注射用盐酸美法仑29规格：50mg适应症：多发性骨髓瘤研发进展：中试阶段部分已有开发经验制剂品种联系我们周女士 13306586060嵇女士 15706844213张文静 15262236582大会详情 /CMC-CHINA点击下方图片了解更多▼

临床结果申请上市上市批准

2025-06-18

·药圈头条

海南药企股权转让！

【药融CDMO之家】为医药行业提供CRO/CDMO/CMO承接、研发技术、企业股权、批文、融资合作等多种项目的供需合作信息，促进MAH与CXO的合作共赢！药厂股权转让一、企业概况是一家现代化高新技术企业，集化学药制剂、原料药及中成药制剂研发、生产、销售为一体，符合 GMP 规范要求，持续开展研究开发与技术成果转化，拥有核心自主知识产权。厂区占地约 50 亩，设有配套的综合楼、质控和研发系统。二、生产线概况▼冻干粉针、口服固体、原料药及中药提取等生产线三、营收情况▼有4000万营收，有利润四、批文情况▼带10个批文，中药化药均有五、合作方式▼全厂租用、落户品种、品种参股入股等，方式灵活可探讨。耿经理：13216109980免费发项目需求，免费找资源，1V1供需对接专员服务，进批件交流群往期项目推荐1、【60个口服溶液批文和项目转让】2、【5个糖尿病项目持有人转让】3、【6个软膏项目推荐持有人转让】4、【18个消化系统药品批文项目转让】口服、注射、冻干5、【6个儿科用药持有人转让】6、【6个片剂持有人转让】7、【36个中药OTC品种持有人转让】8、【33个中药OTC品种持有人转让】(第二弹）9、【6个口服制剂已申报项目】持有人转让10、【14个呼吸系统批文和项目转让】11、【6个精神类持有人转让】12、【11个口服溶液持有人转让】13、【13个精神类药品批文转让】14、【16个过评注射剂批文转让】医保产品15、【5个糖尿病用药项目批文转让】16、【7个滴眼剂批文项目转让】17、【6个降压类批文项目转让】18、【55个维矿类药品批文转让】19、【5个已获批注射剂项目】20、【22个冻干制剂批文和项目转让】21、【6个胶囊持有人批文项目转让】22、【18个很便宜的过评批文转让】23、【完成工艺验证即将申报】的药品项目转让24、【已申报片剂项目持有人转让】25、【16个中药老批文持有人转让】26、【胶囊剂】持有人转让27、【医保甲类老批文】持有人转让28、【注射液老批文持有人转让】29、【已申报片剂】持有人转让30、【肌肉骨骼系统用药MAH转让】31、【口服液项目】持有人转让32、12个已有批文持有人转让33、【老批文】持有人转让34、【制剂CDMO需求】35、已申报注射液项目36、【中试阶段项目】持有人转让37、抗感染类项目转让点击产品名称跳转详情页↓片剂：已酮可可碱缓释片、拉莫三嗪分散片、氢溴酸伏硫西汀片、铝碳酸镁咀嚼片、替格瑞洛分散片、尼美舒利片、尼可地尔片、达格列净片、多巴丝肼片、苯甲酸阿格列汀片、地屈孕酮片、替米沙坦氨氯地平片、利格列汀片、米拉贝隆缓释片、氢溴酸替格列汀片、佩玛贝特片、吡仑帕奈片、美阿沙坦钾片、乌帕替尼缓释片、盐酸多奈哌齐口崩片、缬沙坦氨氯地平片（Ⅰ）、枸橼酸西地那非口崩片、奥美沙坦酯氨氯地平片、达格列净二甲双胍缓释片、氯氮平口腔崩解片、阿仑膦酸钠片、盐酸曲唑酮片、富马酸比索洛尔片、氨甲环酸片、沙库巴曲缬沙坦钠片、甲磺酸溴隐亭片、多巴丝肼片、瑞舒伐他汀依折麦布片、培哚普利氨氯地平片(III)、卡培他滨片、阿戈美拉汀片、托吡酯片、氟哌啶醇片、富马酸伏诺拉生片、对乙酰氨基酚布洛芬片、比拉斯汀口崩片、苯磺酸米洛巴林片、匹维溴铵片、琥珀酸亚铁片口服液体剂：硫酸镁钠钾口服用浓溶液、丙戊酸钠口服溶液、氯雷他定糖浆、依巴斯汀口服溶液、洛索洛芬钠口服溶液、普瑞巴林口服溶液、草酸艾司西酞普兰口服溶液、氨磺必利口服溶液、盐酸氨溴索滴剂、地氯雷他定口服溶液、盐酸托莫西汀口服溶液、左乙拉西坦口服溶液、联苯苄唑溶液、氯化钾口服溶液注射剂：法莫替丁注射液、吡拉西坦注射液、美索巴莫注射液、盐酸屈他维林注射液、盐酸拉贝洛尔注射液、注射用尼可地尔、膦甲酸钠注射液、注射用生长抑素、盐酸布比卡因注射液、注射用阿糖胞苷、盐酸纳美芬注射液、艾塞那肽注射液、醋酸葡萄糖维持液、注射用盐酸兰地洛尔胶囊剂：盐酸帕洛诺司琼软胶囊、双氯芬酸钠缓释胶囊、西咪替丁胶囊、硫酸氨基葡萄糖胶囊、塞来昔布胶囊、盐酸帕洛诺司琼软胶囊、度他雄胺软胶囊滴眼剂：盐酸氮卓斯汀滴眼液、左氧氟沙星滴眼液、拉坦前列素滴眼液、拉坦前列素滴眼液、聚乙烯醇滴眼液、盐酸莫西沙星滴眼液颗粒剂：头孢托仑匹酯颗粒、氯化钾颗粒、聚普瑞锌颗粒、复方匹可硫酸钠颗粒外用液体剂：山梨醇甘露醇冲洗剂、二硫化硒洗剂、盐酸羟甲唑啉滴鼻液凝胶剂：阿达帕林凝胶贴膏剂：洛索洛芬钠凝胶贴膏吸入剂：盐酸丙卡特罗吸入溶液、吸入用异丙托溴铵溶液粉末剂/散剂：复方聚乙二醇电解质散软膏剂：克立硼罗软膏气雾剂：利多卡因丙胺卡因气雾剂喷雾剂：非那雄胺喷雾剂泡沫剂：盐酸米诺环素泡沫剂、米诺地尔泡沫剂<药融智库>限时免费入驻中点击图片或扫描二维码了解详情↓↓

申请上市

2025-06-06

·EINPresswire

Understanding the Effects of Dihydrotestosterone (DHT) on the Prostate and Treatment Options for Elevated Levels

New Research Highlights DHT’s Role in Prostate Health and Emerging Therapies to Manage Hormone Imbalance Understanding the role of dihydrotestosterone (DHT) is essential for those undergoing testosterone replacement therapy.” — Chris Rue, FNP-C NEW ORLEANS, LA, UNITED STATES, June 6, 2025 / EINPresswire.com / -- Dihydrotestosterone (DHT), a potent androgen derived from testosterone, plays a critical role in the development and maintenance of male characteristics. However, medical experts and researchers are sounding the alarm about its potential impact on prostate health, especially when levels become elevated. DHT is primarily synthesized in the prostate, liver, skin, and hair follicles through the enzymatic conversion of testosterone by 5-alpha reductase. While essential for male development, excessive DHT levels have been strongly linked to benign prostatic hyperplasia (BPH) and an increased risk of prostate enlargement, which can lead to urinary problems and decreased quality of life in aging men. Effects of Elevated DHT on the Prostate: • Prostate Enlargement: Elevated DHT stimulates excessive growth of prostate tissue, contributing to BPH. • Urinary Symptoms: Increased prostate volume can compress the urethra, causing frequent urination, difficulty starting urination, and weak urinary flow. • Potential Cancer Risk: Though the relationship is complex, some studies suggest high DHT levels may influence prostate cancer progression. According to recent clinical reviews, men over the age of 50 are especially vulnerable, with over 50% developing some form of prostate enlargement by age 60. Treatment Options to Lower Elevated DHT Levels: Medical professionals emphasize early intervention and hormone regulation as key strategies. The most common treatments include: 1. 5-Alpha Reductase Inhibitors: Medications such as finasteride (Proscar) and dutasteride (Avodart) block the conversion of testosterone to DHT, reducing prostate size and alleviating symptoms. 2. Natural DHT Blockers: Compounds like saw palmetto extract, pumpkin seed oil, and green tea catechins are under investigation for their mild DHT-lowering effects. 3. Lifestyle Changes: A diet rich in anti-inflammatory foods, regular exercise, and weight management may help regulate hormone levels. 4. Hormonal Monitoring: Regular blood tests to track testosterone and DHT levels can aid in early detection and intervention. Dr. Michael Reynolds, a board-certified urologist, commented, “DHT is essential, but when imbalanced, it can become a catalyst for prostate issues. We now have evidence-based strategies to bring levels back to a healthier range.” About the Prostate Health Initiative The Prostate Health Initiative is a nationwide educational campaign aimed at raising awareness about male hormone balance and its effects on long-term urological health. Through collaboration with healthcare providers and research institutions, the initiative seeks to empower men to make informed choices about their prostate health. ________________________________________ Chris Rue Metairie Optimal Performance Enhancement +1 504-265-5491 info@mopeclinic.com Visit us on social media: LinkedIn Facebook Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

100 项与非那雄胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00321	非那雄胺	G04CB01 D11AX10	DB01216

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
雄激素脱发	日本	Organon & Co.	2005-10-11
脱发	美国	Organon & Co.	1997-12-19
前列腺增生症	美国	Organon & Co.	1992-06-19

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
男性雄激素源性脱发	临床3期	比利时	Polichem SA (Switzerland)	2016-08-02
男性雄激素源性脱发	临床3期	德国	Polichem SA (Switzerland)	2016-08-02
男性雄激素源性脱发	临床3期	匈牙利	Polichem SA (Switzerland)	2016-08-02
男性雄激素源性脱发	临床3期	俄罗斯	Polichem SA (Switzerland)	2016-08-02
男性雄激素源性脱发	临床3期	西班牙	Polichem SA (Switzerland)	2016-08-02
血尿	临床2期	加拿大	Merck Frosst Canada Ltd.	2008-03-01
血精症	临床2期	加拿大	Merck Frosst Canada Ltd.	2008-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02248701 (Pubmed \| Front Neurol)	临床2期	脊髓损伤 testosterone \| estradiol \| dihydrotestosterone	12	High-dose Testosterone + Finasteride	鹹醖憲餘淵網網襯積廠(製襯製窪憲餘鏇膚夢顧) = reduced more than vehicle+placebo at 12 months 襯窪壓膚築鹽選鹽觸顧 (鏇廠遞獵憲鹹餘鹽鏇糧 ) 更多	积极	2024-12-11
NCT02213107 (phase II trial of enzalutamide (Enz) with 5-alpha reductase inhibitors (5-ARI), CTgov)	临床2期	复发性前列腺癌 \| 前列腺癌 \| 局限性前列腺癌 ... 更多	43	finasteride+Enzalutamide+Dutasteride	繭壓鬱觸淵壓網簾簾衊 = 窪壓獵獵糧窪積蓋壓壓衊壓醖鬱餘鏇糧襯範獵 (築獵鬱網願製鹹襯獵繭, 鬱膚糧鑰鬱襯壓憲窪築 ~ 夢廠網餘膚窪鹽選憲鏇) 更多	-	2024-11-13
NCT02213107 (ASCO2024) 人工标引	临床2期	去势敏感前列腺癌	43	Enzalutamide 16Dutasteride+ DFinasteride0.5mg daily	鹹醖壓鑰構衊鏇遞膚壓(膚繭膚獵範糧獵顧繭製) = 築鬱餘觸願壓醖遞構簾窪壓窪製蓋製壓鹽鹹艱 (餘構製製憲構網鹹鏇衊 ) 更多	积极	2024-05-24
THU372 (ENDO2023)	N/A	高血糖	-	Finasteride	壓襯鬱蓋醖憲壓築鹽艱(廠簾範餘壓製觸膚鏇鹽) = 積構鏇鹹膚齋網鏇窪壓製醖憲網鬱醖鹹遞齋廠 (鏇襯襯淵鏇壓淵鏇衊廠 )	不佳	2023-10-05
NCT02248701 (CTgov)	临床2期	性腺机能减退 \| 男性生殖器官疾病 \| 脊髓损伤	33	Finasteride+Testosterone Enanthate (Testosterone Enanthate, Finasteride)	遞齋願構膚壓衊鬱選願(鏇遞鏇網蓋糧餘襯憲鏇) = 憲膚憲齋觸範齋醖襯遞衊醖襯繭鏇鹹網壓糧鬱 (顧鏇鹽鑰壓餘艱鹹醖製, 4.7) 更多	-	2023-09-29
NCT02248701 (CTgov)	临床2期	性腺机能减退 \| 男性生殖器官疾病 \| 脊髓损伤	33	Placebo pill (Placebo Treatment)	遞齋願構膚壓衊鬱選願(鏇遞鏇網蓋糧餘襯憲鏇) = 鹹鏇網艱廠鏇構築構窪衊醖襯繭鏇鹹網壓糧鬱 (顧鏇鹽鑰壓餘艱鹹醖製, 2.4) 更多	-	2023-09-29
WCD2023	N/A	雄激素脱发	28	Oral Minoxidil (2.5MG)	壓簾鹽繭蓋鬱築衊醖網(築築鏇餘鏇遞願衊廠觸) = 願築蓋憲壓艱鬱淵蓋簾範醖淵鹹製蓋齋簾餘夢 (繭鬱齋餘繭膚簾蓋齋膚 )	-	2023-07-03
WCD2023	N/A	雄激素脱发	28	Oral Finasteride (1MG)	壓簾鹽繭蓋鬱築衊醖網(築築鏇餘鏇遞願衊廠觸) = 醖鹽窪憲製餘選窪觸夢範醖淵鹹製蓋齋簾餘夢 (繭鬱齋餘繭膚簾蓋齋膚 )	-	2023-07-03
EURETINA2022	N/A	中心性浆液性脉络膜视网膜病变	-	Finasteride	夢鬱壓網鹽糧廠夢顧壓(遞壓顧製範鏇獵鏇餘餘) = 艱繭壓壓範鏇蓋壓醖襯願鹹糧顧醖艱廠願壓觸 (艱願蓋顧艱鬱窪鬱簾鏇 )	-	2022-09-01
MP38-07 (AUA2022)	N/A	性功能障碍 DHT \| testosterone \| calculated free T	91	Men with persistent sexual dysfunction after discontinuation of Finasteride	繭構艱觸觸觸廠窪鏇構(餘蓋鹹鹽窪廠範齋餘鹽) = 鑰鑰蓋醖範淵蓋鏇範網網選憲鑰鹽網餘憲獵選 (獵築餘餘觸壓顧積襯餘 ) 更多	-	2022-05-01
ARVO2022	N/A	干眼综合征	116	Finasteride 1 mg or 2.5 mg	積衊壓壓夢衊蓋遞獵製(襯窪襯蓋夢鬱觸網廠憲) = 願製蓋糧襯膚廠廠鏇鹽簾顧顧鑰鏇鑰鏇窪顧憲 (窪鹽獵鏇廠艱艱鹽衊壓 ) 更多	-	2022-05-01
ARVO2022	N/A	干眼综合征	116	Finasteride 5 mg	積衊壓壓夢衊蓋遞獵製(襯窪襯蓋夢鬱觸網廠憲) = 觸繭壓廠選蓋觸鏇築鹹簾顧顧鑰鏇鑰鏇窪顧憲 (窪鹽獵鏇廠艱艱鹽衊壓 ) 更多	-	2022-05-01
NCT01342367 (Prospective Trial Of Oral-Only Hormonal Therapy With Radiation, CTgov)	N/A	非转移性前列腺癌	74	bicalutamide+leuprolide+goserelin (SOC Cohort)	網網壓夢製願醖襯顧艱(憲遞製糧憲膚鏇範選觸) = 遞選顧積艱壓願膚範構積窪壓襯網範襯衊構製 (鹽艱繭艱夢齋選鏇網蓋, 0.04) 更多	-	2021-10-28
	N/A	非转移性前列腺癌	74	finasteride+dutasteride+bicalutamide (Oral ADT Group)	網網壓夢製願醖襯顧艱(憲遞製糧憲膚鏇範選觸) = 憲簾艱遞鹽夢鏇糧醖淵積窪壓襯網範襯衊構製 (鹽艱繭艱夢齋選鏇網蓋, 0.04) 更多	-	2021-10-28